Pharmaceutical Fronts (Mar 2022)

Design, Synthesis, and Evaluation of Benzoheterocyclic-Containing Derivatives as Novel HDAC1 Inhibitors

  • Min-Ru Jiao,
  • Bo Han,
  • Xiu Gu,
  • Hao Zhang,
  • Ai-Ping Wang,
  • Qing-Wei Zhang

DOI
https://doi.org/10.1055/s-0042-1743487
Journal volume & issue
Vol. 04, no. 01
pp. e22 – e29

Abstract

Read online

Abstract In this study, the synthesis and biological evaluation of a variety of benzoheterocyclic-containing benzamide derivatives were described. Some of these compounds were proved to inhibiting the activity of histone deacetylase 1 (HDAC1) with IC50 values below the micromolar range, retarding proliferation of several human cancer cells, and surprisingly, not possessing toxicity to human normal cells and hERG K+ ion channels. Among those compounds, 3c was the most potent and efficacious derivative. Compound 3c was orally active and displayed excellent in vivo antitumor activity in a HCT-116 xenograft mice model.

Keywords